论文部分内容阅读
有可能作为２型糖尿病新的治疗手段的促胰岛素激素——胰升糖素样多肽１（ＧＬＰ－１），能被广泛存在的氨基－二肽酰肽酶ＩＶ（ｄｉｐｅｐｔｉｄｙｌｐｅｐｔｉｄａｓｅＩＶ，ＤＰＰ－ＩＶ）极快地代谢，其产生的代谢产物可拮抗ＧＬＰ－１受体。因此，单次注射ＧＬＰ－１的作
It is possible that insulin-like glucagon-like polypeptide 1 (GLP-1), a novel dipeptidylpeptidase IV (DPP-IV) electrode that can be widely used as a new treatment for type 2 diabetes Quickly metabolized, the metabolites produced can antagonize the GLP-1 receptor. Therefore, a single injection of GLP-1 for